Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q1 FY24 Earnings Presentation
16 slides from Ngl Fine-chem's earnings presentation, Aug 10, 2023
Slide 1: Cover letter to stock exchanges
o NGL Fine-Chem Limited Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com August 10, 2023 To, Listing Department, Listing D
Slide 2: Investor Presentation Q1FY24
ONGL Fine-Chern Ltd NGL Fine-Chem Limited INVESTOR PRESENTATION Q1FY24
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof ) delivered or supplied should not be
Slide 4: Inside This Presentation
Inside Pg. No. Pg. No. This Presentation 04 08 Q1FY24 Over view, Highlights Key Strengths and Strategy Pg. No. 13 Historical Financial Performance
Slide 5: Q1FY24 Highlights
01 Q1FY24 Highlights 05 06 M A N A G E M E N T C O M M E N TA R Y Q UA R T E R LY O P E R AT I O N A L M E T R I C S • } 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, However, it is important to highlight that, despite these challenges, we've managed to stand firm. Our I am pleased to provide you with an update on our market share in our products remains intact, a performance for Q1FY24. testament to our resilience, especi
Slide 7: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q1FY23 Q4FY23 Q1FY24 PARTICULARS Q1FY23 Q4FY23 Q1FY24 ANIMAL API 88% 81% 87% TOP 3 PRODUCTS 34% 41% 34% HUMAN API 4% 3% 3% TOP 5 PRODUCTS 51% 58% 50% INTERMEDIATES 3% 11% 7% TOP 10 PRODUCTS 75% 78% 73% FORMULATIONS 5% 4% 3%
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q1FY23 Q4FY23 Q1FY24 Q-o-Q Y-o-Y REVENUE FROM OPERATIONS 64.61 73.89 71.04 -3.86% 9.95% OTHER INCOME 3.14 2.1 3.32 58.10% 5.73% TOTAL INCOME 67.75 75.99 74.36 -2.15% 9.76% TOTAL OPERATING EXPENSES 63.11 60.92 61.18 0.43% -3.06% EBITDA 1.5
Slide 9: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 09 10 L E A D I N G A N I M A L H E A LT H C O M PA N Y LEADERSHIP IN VETERINARY API SEGMENT • } 11 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 12 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 10: Leading Animal Health Company
Leading Animal Health Company ••• ~11 COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 26 APIs (24 Veterinary • Leadership in top • 3 state of the art • 45+ countries across • ~400 customers APIs
Slide 11: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 15% CAGR CONCENTRATION (OF SALES FY23) backward integrated facilities leading to cost competitiveness FY23 225 CUSTOMER PRODUCT F
Slide 12: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 13: Strategy for next leg of growth
Strategy for next leg of growth ••• BROWNFIELD EXPANSION • •• ~~ • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • 50% capacity e
Slide 14: Historical Financial Performance
03 Historical Financial Performance 14 ROBUST FINANCIAL PERFORMANCE • }
Slide 15: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 FY19 153 FY19 32 FY19 20 0 50 100 150 200 250 300 350 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GROSS MA
Slide 16: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 ONGl Fine-Chern ltd Corporate Office 301, E-square, Subhash Road, Vile Parle (East)